DMRA (Damora Therapeutics) Insider Ownership: 1.86 % (As of Aug. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMRA Damora Therapeutics Inc DMRA
28 GF Score
Price $29.94
! 3 Warning Signs
View Full Analysis

What is Damora Therapeutics Insider Ownership?

Damora Therapeutics DMRA +1.10% 28 Insider Ownership is 1.86 % as of Aug. 11, 2026. GuruFocus rates DMRA with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Damora Therapeutics's insider ownership is 1.86%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Damora Therapeutics's Institutional Ownership is 91.24%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Damora Therapeutics's Float Percentage Of Total Shares Outstanding is 85.61%.

Damora Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Damora Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Damora Therapeutics Insider Ownership Chart

Damora Therapeutics Historical Data

The historical data trend for Damora Therapeutics can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 4.00 3.99 3.99 3.99 3.82 32.33 1.07 1.86 1.86 1.86
DMRA
28GF Score
Damora Therapeutics Inc DMRA
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Damora Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 1.86 % mean?
Damora Therapeutics (DMRA) has a Insider Ownership of 1.86 % as of Aug. 11, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Damora Therapeutics and its competitors.
Is Damora Therapeutics' Insider Ownership too high?
Damora Therapeutics' current Insider Ownership is 1.86 %. Overall, Damora Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Damora Therapeutics' Insider Ownership compare to SLBT and BCAX?
Damora Therapeutics' Insider Ownership of 1.86 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Damora Therapeutics and its competitors. Damora Therapeutics's current Insider Ownership is 1.86 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Damora Therapeutics stock overvalued right now?
Damora Therapeutics (DMRA) has a current Insider Ownership of 1.86 %. The current Insider Ownership is 1.86 %. Damora Therapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Damora Therapeutics (DMRA), the current Insider Ownership is 1.86 % as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Damora Therapeutics Business Description

Address 221 Crescent Street, Building 23, Suite 105, Waltham, MA, USA, 02109
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
28GF Score

Get the complete analysis for DMRA

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.94
Price